Articles Archive: September - October 2015 Issue 68

Editorial - Goodbye or arrivederci?


Our new vocabulary – gene, genome, molecular, targeted, personalised – no longer inspires the confidence it once did, and as the cancer community prepares to gather at the 18th ECCO - 40th ESMO European Cancer Congress in Vienna, there is a real sense of uncertainty about where the next major progress will come from, writes Alberto Costa in this editorial.

Cover Story - Denis Lacombe quietly orchestrating the clinical research revolution


The scientific complexity and economic cost of developing new cancer therapies demand a level of collaboration and sharing that takes both industry and academia well beyond their comfort zones. EORTC head Denis Lacombe believes he has the passion and the vision to help make it happen.

Cutting Edge - What can we learn from liquid biopsies?


Early detection, disease prognosis, a guide to treatment, a key to unlock the secrets of how cancers evolve. Researchers have high hopes for what they can learn from the biological detritus shed by primary tumours and metastases.

Best Cancer Reporter Award - Asking the dumb questions


It took ten years of immersion in the world of cancer research to produce the book that won Clifton Leaf a Best Cancer Reporter Lifetime Achievement award. But it started from a simple question: how do claims about winning the war on cancer square with a failure to cut death rates?

Cross Talk - Does lack of physical exercise jeopardise a patient's chances of survival?


Exercise reduces the risks of getting some cancers – but what about after diagnosis? What should we be advising our patients?

Spotlight on... - Championing healthcare in an age of austerity: an interview with the European Health Commissioner


Vytenis Andriukaitis talks to Cancer WorldÂ’s Anna Wagstaff about what Europe needs to do to safeguard and extend access to high-quality cancer care in challenging times.

e-Grand Round - Are progression-free and disease-free survival the new gold standard for cancer trials?


Showing that a new drug can keep advanced cancers from progressing, or stop early cancers from returning, is quicker, cheaper and easier than showing that it helps patients live longer. But how can we judge in which instances these surrogates will accurately predict overall survival?

Patient Voice - Rerouted, not derailed: resuming a young life after cancer


Paediatric oncologists are highly focused on how to minimise and manage the life-long damage their treatments inflict on young patientsÂ’ health. But for young survivors, the most immediate challenge is how to get an interrupted life back on track.

Focus - The moment medical students discover a profound appreciation for humanity


A great short piece by medical student Armaan Rowther flagging up the role of anatomy labs in shaping medicsÂ’ attitudes towards their future patients. "Is the language of medicine that is learned in anatomy lab limited to anatomical vocabulary or does it extend to our less technical conversations about patients, and even the extent to which our words respect and humanise the people in our care?" he asks

Newsround - Newsround

Selected reports edited by Janet Fricker